AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 232 min read$ORKA

Oruka Reports Positive Week 28 Results For ORKA-001 In Plaque Psoriasis; Stock Down

Oruka Therapeutics (ORKA) reported positive Week 28 results for ORKA-001 in a Phase 2a trial for plaque psoriasis, showing improved responses and a favorable safety profile. The stock is down 5.87% in pre-market trading.

Original reporting
rttnews.com
Published Sep 23, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$ORKA
Bullish
high confidence
Mentioned
$ORKA
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ORKABullishMed
01

Why it matters

The Week 28 data provides the first efficacy readout for ORKA-001, a key milestone for the company's valuation.

02

Market read

First disclosure of pivotal trial data; likely to move ORKA stock and influence related biotech peers.

03

What to watch

Small trial size (84 patients) and lack of long‑term safety data may temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Oruka Therapeutics is a clinical‑stage biotech focused on IL‑23p19 antibodies for dermatologic diseases.

Company-level read

Ticker impact

$ORKABullishHigh confidence
Context

Oruka Therapeutics disclosed positive Week 28 Phase 2a EVERLAST-A data, with 71.4% PASI 100 and 87.3% PASI 90 responses.

Expected impact

Potential short-term upside as the market digests the data; price may rise 5‑10% if broader market conditions stay supportive.

Evidence & confidence

Phase 2a data with high complete clearance rates is material for a biotech; investors typically reward such news, especially for a company with limited pipeline.

Market effects

Sector

Positive read on IL‑23p19 antibody space; may lift peers developing similar biologics.

Regional

U.S. biotech sector could see modest gains in early trading.

Global

Limited to biotech investors; no broad macro effect.

Counterpoint

What could challenge this read

If later-stage data fails to confirm durability, the initial hype could reverse sharply.

Key entities

  • company
    Oruka Therapeutics, Inc.

    Biotech developing ORKA-001 for plaque psoriasis.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 1
$ORKAMedAI 8/10

How Investors Are Reacting To Oruka Therapeutics (ORKA) Positive Psoriasis Trial Results

Oruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A Phase 2a trial for ORKA-001 in treating moderate-to-severe plaque psoriasis. The drug showed high PASI 90 and PASI 100 response rates, maintained IGA 0/1 responses, and had a safety profile consistent with the IL-23p19 class. The company has no revenue, reported a net loss of $109.688m, and relies on clinical trials and funding. The stock is up sharply over the past year but down 10.2% over the last month.

simplywall.st2 min
SEP 23
$ORKAMedAI 8/10

Why is Oruka Therapeutics stock sliding today?

Oruka Therapeutics' stock fell 2.5% in pre-market trading after releasing positive but expected Week 28 trial data, with 71.4% of patients achieving complete skin clearance. The company's Chief Medical Officer highlighted the potential of ORKA-001. A pre-planned insider sale of 10,000 shares and a cautious market backdrop also contributed to the decline. Oruka's Price-to-Sales ratio remains high, reflecting growth expectations. The company plans to share more data in December 2026 and Q4 2026.

investing.com2 min
SEP 23
$ORKAHighAI 9/10

Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

Oruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A trial of ORKA-001, showing PASI 100 and PASI 90 rates increased to 71.4% and 87.3%, respectively, without additional dosing. The drug maintained a favorable safety profile. Full 52-week data is expected in December 2026, with 16-week EVERLAST-B data due in 4Q 2026.

finanznachrichten.de2 min